Analystreport

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $237.00 price target on the stock.

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com